Zanaboni F, Vergadoro F, Presti M, Gallotti P, Lombardi F, Bolis G
III Department of Obstetrics and Gynecology, University of Milan, Italy.
Gynecol Oncol. 1987 Sep;28(1):61-7. doi: 10.1016/s0090-8258(87)80009-4.
Serum CA 125 was measured in 100 patients with ovarian epithelial carcinoma at diagnosis and in follow-up. Levels over 35 U/ml were found in 43 (75.4%) of 57 cases at diagnosis and in 21 (48.8%) of 43 cases in follow-up. A correlation was found between tumor burden and marker positivity: advanced Stages (III and IV) and recurrences had 84.2 and 91% of positivity, compared to 59.1% in early disease (Stages I and II). Analysis by histotype and FIGO grade revealed a difference between the mucinous type and the others and a positive association with less differentiated tumors. In the 30 patients submitted to second-look laparotomy a correlation was found between CA 125 levels and pathological response in 86.7% of cases. This ovarian cancer marker may thus be more useful in monitoring the response to treatment and in long-term follow-up than in diagnosis.
对100例卵巢上皮癌患者在诊断时及随访期间检测血清CA 125。诊断时57例中有43例（75.4%）CA 125水平超过35 U/ml，随访时43例中有21例（48.8%）超过该水平。发现肿瘤负荷与标志物阳性之间存在相关性：晚期（III期和IV期）及复发患者的阳性率分别为84.2%和91%，而早期疾病（I期和II期）患者的阳性率为59.1%。按组织学类型和国际妇产科联盟（FIGO）分级分析显示，黏液性类型与其他类型存在差异，且与分化程度较低的肿瘤呈正相关。在接受二次剖腹探查的30例患者中，86.7%的病例显示CA 125水平与病理反应之间存在相关性。因此，这种卵巢癌标志物在监测治疗反应和长期随访中可能比在诊断中更有用。
